GlassScriptPhysician profile
Daniel W Mead
NPI 1225593726
$5,033.63
in general payments reported to CMS, 2019-2025
30 companies · $2,181 in 2025
The $2,181 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,099 · 2022: $581 · 2023: $894 · 2024: $278 · 2025: $2,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.10 |
| Education | $267.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $997.84 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $691.61 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $676.27 | 2021-2025 | Caplyta |
| Lundbeck LLC | $518.22 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $414.28 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $403.10 | 2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $213.78 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $176.59 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $111.39 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $95.06 | 2024-2025 | Cobenfy |
| Esperion Therapeutics, INC. | $92.56 | 2021 | |
| Lilly USA, LLC | $75.62 | 2021 | |
| Vanda Pharmaceuticals INC. | $69.10 | 2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $63.42 | 2021-2023 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $60.10 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.43 | 2025 | Invega Sustenna, Spravato |
| Amgen INC. | $41.77 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.53 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $30.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.97 | 2021 | |
| Kaleo, INC. | $27.11 | 2021 | |
| Adlon Therapeutics L.P. | $26.95 | 2021 | |
| Tris Pharma INC | $22.53 | 2025 | Dyanavel Xr |
| Optinose US, INC. | $21.45 | 2021 | |
| Sage Therapeutics, LLC | $18.99 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $15.77 | 2025 | Secuado |
| Vertical Pharmaceuticals, LLC | $15.08 | 2025 | Relexxii |
| Endo Pharmaceuticals INC. | $14.19 | 2021 | |
| Bausch Health US, LLC | $13.50 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.